771 related articles for article (PubMed ID: 32005945)
1. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
Buscail L; Bournet B; Cordelier P
Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):153-168. PubMed ID: 32005945
[TBL] [Abstract][Full Text] [Related]
2. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
Trisolini E; Armellini E; Paganotti A; Veggiani C; Bozzola C; Frattini M; Pizio C; Mancuso G; Andorno S; Boldorini R
Pathology; 2017 Jun; 49(4):379-386. PubMed ID: 28450086
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
5. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
[TBL] [Abstract][Full Text] [Related]
7. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
[TBL] [Abstract][Full Text] [Related]
8. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
12. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
Mansour Y; Boubaddi M; Odion T; Marty M; Belleannée G; Berger A; Subtil C; Laurent C; Dabernat S; Amintas S
Cancer Cytopathol; 2024 May; 132(5):274-284. PubMed ID: 38308613
[TBL] [Abstract][Full Text] [Related]
13. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
[TBL] [Abstract][Full Text] [Related]
16. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
17. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
18. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
19. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
20. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]